<DOC>
	<DOCNO>NCT00045864</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness combination therapy Proleukin Rituxan patient intermediate-and high- grade Non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Proleukin Combination With Rituxan Patients With Intermediate High-Grade Non-Hodgkin 's Lymphoma .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion : Diagnosis : CD20+ Bcell nonHodgkin 's lymphoma ( NHL ) classify intermediate highgrade accord Working Formulation , subtypes D H. Must measureable progressive refractory disease three prior chemotherapy regimen . Exclusion : Clinically significant cardiac dysfunction , history myocardial infarction heart failure within 6 month first study treatment Clinically significant pulmonary dysfunction . Liver disease ( note hepatitis C seropositive subject may enrol active disease demonstrate undetectable HCV viral load , biopsy show active disease , and/or history normal transaminase least three different date within one year first study treatment ) . Symptomatic thyroid disease require medical intervention replacement treatment hypothyroidism . History autoimmune disease . History positive serology human immunodeficiency virus ( HIV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2006</verification_date>
	<keyword>Intermediate High-Grade Non-Hodgkin 's Lymphoma</keyword>
</DOC>